Home Health How COVID-19 treatment is related to malaria drugs?
HealthNews

How COVID-19 treatment is related to malaria drugs?

Share
COVID-19
Share

Russia’s Federal Biomedical Agency on Saturday said it has developed a drug for the treatment of COVID-19.

The agency said its drug was based on mefloquine, which is used to prevent or treat malaria.

The drug will allegedly provide effective treatment for COVID-19 patients with varying severity.

According to the agency’s statement, the drug prevents virus replication in cells and as a result, stops the inflammatory process caused by the virus.

Veronika Skvortsova, the agency’s head, said Mefloquine has to be combined with antibiotics for the maximum effect, allowing an increase in the concentration of antiviral agents in blood plasma and lungs.

This will ensure effective treatment of patients with various degrees of coronavirus infection, Skvortsova said.

The agency said it was developing an effective and safe scheme for the prevention of coronavirus on the basis of mefloquine.

The treatment was developed taking Chinese and French experience into account, it added.

COVID-19 treatment, for now, focuses on relieving symptoms such as breathing assistance.

Companies around the world are racing to develop vaccines. A few have launched early safety testing in humans, but experts say it could take a year or more to develop and test a vaccine.

Although Russia claims to have found the cure based on malaria treatment drug, Confiance News gathered that Donald Trump had earlier affirmed to the use of chloroquine, also a drug known for the treatment of malaria, owing to its effectiveness in treating COVID-19 patients.

“HYDROXYCHLOROQUINE & AZITHROMYCIN, taken together, have a real chance to be one of the biggest game changers in the history of medicine. The FDA has moved mountains – Thank You! Hopefully they will BOTH (H works better with A, International Journal of Antimicrobial Agents)…..,” he tweeted.

However, leading infectious disease experts have urged the public to remain cautious until larger clinical trials validate smaller studies.

 

(DAILY SABAH)

Please follow and like us:
Share

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Member

Don't Miss

‎Why Nigeria’s Banks Still on Shaky Ground with Big Profits, Weak Capital

By Blaise Udunze‎‎Despite the fragile 2024 economy grappling with inflation, currency volatility, and weak growth, Nigeria’s banking industry was widely portrayed as successful...

Why 2026 could be your year of extraordinary breakthroughs‎

By Chioma Obinagwam‎‎Year 2026 will mark the end of ordinary living for those willing to embrace divine discipline and fervent pursuit of God.‎‎Confiance...

Related Articles

Why 2026 could be your year of extraordinary breakthroughs‎

By Chioma Obinagwam‎‎Year 2026 will mark the end of ordinary living for...

‎Seplat Energy ends routine gas flaring, leads Nigeria’s net-zero drive‎

By Chioma Obinagwam‎‎ Seplat Energy Plc is reinforcing its commitment to responsible,...

‎What Ghana’s Crypto Regulation Actually Means for Businesses‎

By Gillian Darko, Vice President of Strategy, Yellow Card‎‎Across Africa, 2025 marked...

How Strategic Visibility Shapes Trust, Growth and Influence‎

By Yinka Olaito Business visibility is no longer a cosmetic add-on but...